Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha; Alexander T.H. Wu; Wei-Hwa Lee; Liang-Shun Wang; Wan-Wan Lin; Chiou-Chung Yuan; Chi-Tai Yeh

doi:10.18632/oncotarget.3658

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha, Alexander T.H. Wu, Wei-Hwa Lee, Liang-Shun Wang, Wan-Wan Lin, Chiou-Chung Yuan and Chi-Tai Yeh _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:13255-13268. https://doi.org/10.18632/oncotarget.3658

Metrics: PDF 2773 views | HTML 4310 views | ?

Abstract

Muhammad Ary Zucha1,2, Alexander T.H. Wu3,4, Wei-Hwa Lee5, Liang-Shun Wang6, Wan-Wan Lin1, Chiou-Chung Yuan7, Chi-Tai Yeh6,8

1 Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan

2 Department of Obstetrics and Gynecology, Gadjah Mada University-Sardjito Central Hospital, Yogyakarta, Indonesia

3 Graduate Institute of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

4 Translational Research Laboratory, Cancer Center, Taipei Medical University Hospital, Taipei, Taiwan

5 Department of Pathology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan

6 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

7 Obstetrics and Gynecology Department, Shuang-Ho Hospital, Taipei, Taiwan

8 Department of Medical Research and Education, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan

Correspondence to:

Chi-Tai Yeh, email:

Chiou-Chung Yuan, email:

Keywords: ovarian cancer, cancer stem cell (CSC), spheroids, ibrutinib, Bruton’s tyrosine kinase (Btk), cisplatin

Received: December 14, 2014 Accepted: February 28, 2015 Published: March 26, 2015

Abstract

According to a Prognoscan database, upregulation of Bruton’s tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non-CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3658

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Abstract